Tags

Type your tag names separated by a space and hit enter

Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations.
Expert Rev Vaccines. 2015; 14(9):1241-53.ER

Abstract

Human norovirus infection causes significant medical and financial costs in the USA and abroad. Some populations, including young children, the elderly, and the immunocompromised, are at heightened risk of infection with this virus and subsequent complications, while others, such as healthcare workers and food handlers are at increased risk of transmitting it, and some are at risk of both. Human noroviruses are heterogeneous with new strains emerging periodically. In addition to viral diversity, incompletely understood characteristics, such as virus-host cell binding and duration of immunity after infection add to the challenges of creating a norovirus vaccine. Although much progress has been made in recent years, many questions remain to be answered. In this review, we discuss the important areas and relevant literature in considering human norovirus vaccine development and potential targets for implementation.

Authors+Show Affiliations

Centers for Disease Control and Prevention, Division of Viral Diseases, Epidemiology Branch, Viral Gastroenterology Team, Atlanta, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26224658

Citation

Aliabadi, Negar, et al. "Progress Toward Norovirus Vaccines: Considerations for Further Development and Implementation in Potential Target Populations." Expert Review of Vaccines, vol. 14, no. 9, 2015, pp. 1241-53.
Aliabadi N, Lopman BA, Parashar UD, et al. Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations. Expert Rev Vaccines. 2015;14(9):1241-53.
Aliabadi, N., Lopman, B. A., Parashar, U. D., & Hall, A. J. (2015). Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations. Expert Review of Vaccines, 14(9), 1241-53. https://doi.org/10.1586/14760584.2015.1073110
Aliabadi N, et al. Progress Toward Norovirus Vaccines: Considerations for Further Development and Implementation in Potential Target Populations. Expert Rev Vaccines. 2015;14(9):1241-53. PubMed PMID: 26224658.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations. AU - Aliabadi,Negar, AU - Lopman,Ben A, AU - Parashar,Umesh D, AU - Hall,Aron J, Y1 - 2015/07/29/ PY - 2015/7/31/entrez PY - 2015/8/1/pubmed PY - 2016/5/3/medline KW - Norwalk agent KW - calciviridae KW - epidemiology KW - gastroenteritis KW - norovirus KW - vaccine development SP - 1241 EP - 53 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 14 IS - 9 N2 - Human norovirus infection causes significant medical and financial costs in the USA and abroad. Some populations, including young children, the elderly, and the immunocompromised, are at heightened risk of infection with this virus and subsequent complications, while others, such as healthcare workers and food handlers are at increased risk of transmitting it, and some are at risk of both. Human noroviruses are heterogeneous with new strains emerging periodically. In addition to viral diversity, incompletely understood characteristics, such as virus-host cell binding and duration of immunity after infection add to the challenges of creating a norovirus vaccine. Although much progress has been made in recent years, many questions remain to be answered. In this review, we discuss the important areas and relevant literature in considering human norovirus vaccine development and potential targets for implementation. SN - 1744-8395 UR - https://www.unboundmedicine.com/medline/citation/26224658/full_citation L2 - http://www.tandfonline.com/doi/full/10.1586/14760584.2015.1073110 DB - PRIME DP - Unbound Medicine ER -